The Flaxil Label (B) Harvard Case Solution & Analysis

This case focuses on the 2001 negotiations between Mytex pharmaceuticals and the U.S. Food and Drug Administration (FDA). Outcome of the negotiations will determine the new label for the blockbuster drug for arthritis Mytex, Flaxil. Negotiations rather qualitative and different from the typical price negotiations with which students are familiar. However, at stake was $ 500 million in sales Flaxil and security of millions of patients. (B) case is the perspectives of the patient and her doctor, as they believe that the new information about the risks Flaxil author. "Hide
by Gregory Barron Source: Harvard Business School 3 pages. Publication Date: August 24, 2008. Prod. #: 909002-PDF-ENG

Share This